Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

The National Institutes of Health (NIH) is seeking applications to investigate the mechanisms through which incretin mimetics impact cancer risk. The goal of this funding announcement is to promote preclinical and patient-based studies examining the effects of these agents on cancer risk. Applicants should propose research that draws on their understanding of the dynamic changes caused by incretin mimetics to investigate how these agents influence cancer risk. The following are key aspects of this opportunity: * The NIH is interested in studies that examine the impact of incretin mimetics on cancer risk, rather than shorter-term outcomes such as weight loss and diabetes. * Applicants should propose research that investigates the mechanisms by which incretin mimetics influence cancer risk. * The NIH encourages applications from talented scientists who understand the dynamic changes caused by these agents. * The funding announcement is open to a wide range of applicant types, including universities, non-profits, and small businesses.